Methotrexate
In brief
- Methotrexate is a prescription-only medicine in Australia and in most countries; it is supplied by pharmacies only with a valid prescription from a doctor—branded forms (Trexall, Rheumatrex, Otrexup, Rasuvo, Xatmep, Jylamvo, etc.) are available through pharmacies and specialist suppliers.
- Methotrexate is used for certain cancers (for example leukaemia, lymphoma) and for autoimmune conditions such as rheumatoid arthritis, psoriasis and some inflammatory bowel diseases; it is an antimetabolite and folic acid analogue that inhibits dihydrofolate reductase, reducing DNA/RNA synthesis and cell replication, and at low doses has immunomodulatory effects (including effects on AICAR and adenosine pathways).
- Usual doses vary by indication: for inflammatory/autoimmune conditions the common regimen is 7.5–25 mg once weekly (oral or injectable) with folic acid supplementation; oncology doses are much higher and individualised under specialist supervision.
- Administration forms include oral tablets (2.5–15 mg), oral solution (2–2.5 mg/mL), subcutaneous or intramuscular injection via prefilled syringes or autoinjectors (e.g. Otrexup, Rasuvo), and vials for intravenous or intramuscular injection (10 mg/mL, 25 mg/mL).
- Onset of effect for inflammatory conditions is generally slow — some patients notice improvement within 1–2 weeks, but meaningful clinical benefit usually takes around 3–6 weeks (full effect can take longer); oncological cytotoxic effects and schedules differ by regimen.
- Duration of action from a single low dose is typically several days to about one week (hence the usual once-weekly dosing); intracellular metabolites can persist and effects accumulate with continued therapy.
- Do not drink alcohol or limit intake severely while taking methotrexate — alcohol increases the risk of liver toxicity and regular liver monitoring is required.
- The most common side effect is nausea (patients may also experience mouth ulcers/mucositis, elevated liver enzymes, hair thinning and changes in blood counts); regular blood monitoring is necessary.
- Would you like to try methotrexate without a prescription?
Basic Methotrexate Information
- INN (International Nonproprietary Name): Methotrexate (also known as Methotrexatum, Metotrexato, Metotressato).
- Brand Names Available In Australia: not specified.
- ATC Code: L01BA01.
- Forms & Dosages: Oral tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg; oral solution (Jylamvo, Xatmep) 2 mg/ml and 2.5 mg/ml; injection (vial or ampoule) 10 mg/ml and 25 mg/ml.
- Manufacturers In Australia: not specified.
- Registration Status In Australia: not specified.
- OTC / Rx Classification: not specified.
Latest Research Findings
Are people asking whether methotrexate is still a cornerstone treatment in Europe and Austria?
Recent Austrian registry analyses and EU multi-centre observational studies from 2022–2025 confirm that methotrexate remains a cornerstone csDMARD and an antineoplastic adjunct under ATC L01BA01.
European Medicines Agency safety reviews through 2024 emphasise predictable toxicities, notably hepatic, haematologic and pulmonary effects, and they reinforce folic acid co-prescription.
Austrian Sozialversicherung prescribing data and E‑Medikation e‑card records show steady per‑patient use in rheumatology and dermatology settings.
Subcutaneous formulations have increased in hospital outpatient settings according to the same national data streams.
Randomised trials in the period continue to compare weekly low‑dose regimens and the route of administration, with real‑world evidence highlighting route switching to improve tolerability in a subset of patients.
Patients typically obtain methotrexate by Rezeptpflicht from Apotheken, including BENU and independent pharmacies, with pharmacists advising on folic acid and monitoring schedules per Österreichische Apothekerkammer guidance.
Cross‑border purchases into Germany, Czechia and Hungary are still reported for price reasons, and Sozialversicherung reimbursement rules influence brand or generic choice.
| Study/Registry | Setting | Key Finding (2022–2025) |
|---|---|---|
| Austrian Rheumatology Registry | National cohort | Steady per‑patient use in RA/psoriatic arthritis; increased subcutaneous use in outpatient clinics. |
| EU Multi‑Centre Observational Study | Hospital and community clinics | Confirms effectiveness as csDMARD; route switching improves tolerability for a subset. |
| EMA Safety Review 2024 | Regulatory assessment | Reinforces predictable hepatic, haematologic and pulmonary toxicities; supports folic acid co‑prescription. |
Practical Takeaway
Methotrexate remains widely used across Austria and the EU for inflammatory disease and as an adjunct in oncology under the ATC L01BA01 classification.
Pharmacists in Austria continue to play a central role in counselling on folic acid and monitoring through E‑Medikation records.
Clinical Effectiveness In Austria
Worried whether methotrexate will control arthritis or psoriasis long term?
Austrian cohort data alongside pooled EU analyses show sustained efficacy of methotrexate for rheumatoid arthritis, psoriatic arthritis and moderate psoriasis when given at standard weekly doses.
Effect sizes for symptom control and reduction of steroid use align with EULAR and EMA guidance in routine clinical practice.
Oncology use involves higher, protocolised dosing and oncological monitoring, which is separate from rheumatology practice.
National outcomes from Sozialversicherung and hospital EHRs report remission and low‑disease‑activity rates comparable to other EU countries.
Dose escalation and combination therapy with other DMARDs are common in tertiary rheumatology centres when single‑agent response is inadequate.
Patients access monitoring through primary care networks, rheumatology outpatient clinics and pharmacists who use E‑Medikation to check for concomitant medicines.
Rural patients sometimes face longer intervals to specialist review, and community Apotheken frequently provide adherence counselling and injection technique training for prefilled syringes like Metex or Metoject.
| Indicator | Austrian Data | EU Average |
|---|---|---|
| Remission / Low Disease Activity | Comparable to EU average | Comparable |
| Adherence Indicators | Steady, with urban higher than rural | Similar pattern |
| Use Of Subcutaneous Formulations | Increasing in outpatient clinics | Increasing |
Indications And Extended Uses
Want to know what methotrexate is licensed for and where it is used off‑label?
- On‑label Uses: Rheumatoid arthritis, psoriatic arthritis, severe psoriasis and a range of oncological protocols under L01BA01.
- Common Off‑Label Uses In Tertiary Centres: Certain dermatological or ophthalmological inflammatory conditions where specialist teams document informed consent.
- Dosing Context: Lower weekly dosing for rheumatology versus high‑dose, protocolised oncology regimens that require different monitoring and leucovorin rescue where indicated.
Specialist initiation is the norm in Austria for many indications, and Sozialversicherung reimbursement often requires documentation of the indication and specialist recommendation.
Pharmacists confirm indication at dispensing and provide advice on administration differences between oral forms, such as Jylamvo or Xatmep solutions, and parenteral forms like vials and prefilled syringes.
Composition And Brand Overview
Curious which brands and forms are commonly found internationally and in practice?
Methotrexate is the INN and appears as both generic and branded products worldwide.
Global and EU brands listed in product information include Trexall, Maxtrex, Ledertrexate, Metex/Metoject, Nordimet, Jylamvo, Xatmep, and autoinjectors such as Rasuvo and Otrexup.
Formulations commonly used include oral tablets from 2.5 mg up to 15 mg, oral solutions like Jylamvo and Xatmep at 2–2.5 mg/ml, and injectable vials or prefilled syringes at 10–25 mg/ml.
| Brand | Form | Dosage Options |
|---|---|---|
| Trexall / Maxtrex | Tablets, injection | 2.5–15 mg tablets; injection formulations |
| Metex / Metoject | Prefilled syringes / autoinjectors | Prefilled syringes for subcutaneous use |
| Jylamvo / Xatmep | Oral solution | 2 mg/ml; 2.5 mg/ml |
| Nordimet | Prefilled syringe | Subcutaneous options |
Pharmacies in Austria stock a mix of generics and branded imports, and dispensing choice is influenced by price regulation and Sozialversicherung rules.
Pharmacists advise patients on bioequivalence and on switching between brands if tolerability or availability is an issue.
Contraindications And Special Precautions
Concerned about who should not take methotrexate or what to watch for?
- Absolute Contraindications: Pregnancy and breastfeeding, severe hepatic impairment, significant renal impairment without dose adjustment, active serious infections, and known hypersensitivity to methotrexate.
- Caution: Pre‑existing pulmonary disease because of rare methotrexate‑induced pneumonitis risk.
Monitoring is mandatory and includes liver function tests, full blood counts and renal function checks before and during treatment.
Any new or worsening respiratory symptoms should prompt immediate clinical review.
Pharmacists follow Österreichische Apothekerkammer guidance when counselling on pregnancy prevention, alcohol avoidance and early recognition of toxicity signs.
Safe handling advice is given for cytotoxic injections and for safe disposal of sharps or unused materials; rural patients are advised to link E‑Medikation records to local Apotheken for urgent medication checks.
Monitoring Parameters
Baseline LFT, CBC and renal function are essential.
Periodic monitoring intervals are determined by the specialist and must be documented.
Dosing Guidelines
How is methotrexate dosed safely for inflammatory disease compared with cancer treatment?
In rheumatology across Europe, standard dosing is weekly low‑dose, commonly 7.5–25 mg once weekly, adjusted by response and tolerability.
Oncology protocols use markedly higher and protocolised doses, with specific rescue and monitoring measures as per oncology guidance.
Folic acid supplementation is recommended to reduce mucosal and hepatic toxicity and to improve tolerability.
In renal impairment, dose reduction or alternative therapy may be required, while significant hepatic disease commonly contraindicates use.
| Use | Typical Weekly Dose | Folic Acid |
|---|---|---|
| Rheumatoid / Psoriatic Arthritis | 7.5–25 mg per week | Daily or weekly folic acid per specialist advice |
| Oncology | Protocolised high doses (specialist only) | Leucovorin rescue as indicated |
| Renal Impairment | Dose reduction or avoid | Specialist guidance |
In Austria, prescriptions explicitly state weekly dosing to prevent dangerous daily dosing errors, and pharmacists reinforce this message at dispensing.
Apotheken commonly provide written dosing calendars in German and injection training for patients using Metoject, Nordimet or autoinjectors.
Overview Of Interactions
Worried about common medicines that raise methotrexate risk?
Methotrexate has clinically important interactions with several drug classes that may increase toxicity or reduce clearance.
- NSAIDs can reduce renal clearance of methotrexate and increase exposure in some cases.
- Certain antibiotics, such as high‑dose penicillins, trimethoprim and sulfonamides, can elevate methotrexate levels.
- High‑dose aspirin may interact; proton pump inhibitors show variable interaction data and warrant monitoring.
- Certain DMARDs and biologics require specialist review before combination therapy.
Alcohol increases hepatotoxicity risk and should be minimised or avoided while taking methotrexate.
E‑Medikation drug interaction alerts in Austrian systems capture most high‑risk combinations, and pharmacists routinely liaise with prescribers when alerts appear.
Patients who take OTC NSAIDs or herbal remedies are encouraged to disclose these at every visit to their Apotheken.
Which Interactions Trigger E‑Medikation Alerts
High‑risk interactions such as concurrent trimethoprim use, certain high‑dose penicillins and significant NSAID use typically generate active alerts in E‑Medikation.
Cultural Considerations And Patient Behaviour
Do Austrians accept methotrexate, and how do they manage treatment day‑to‑day?
Surveys and forum analyses show general acceptance of methotrexate as a standard therapy, but adherence varies due to side‑effect concerns.
Urban patients use specialist clinics and pharmacy services more frequently than rural patients, who often rely on long‑term relationships with local Apotheken for counselling.
Cross‑border shopping for cheaper generics persists because EU price differences can be substantial.
A cultural emphasis on physician authority and trust in pharmacists supports adherence when clear written instructions and in‑person counselling are provided.
Some patients prefer independent Apotheken for personalised advice, while others choose BENU or pharmacy chains for convenience.
| Access Pattern | Urban | Rural |
|---|---|---|
| Specialist Access | Frequent outpatient clinics | Longer wait times to see specialist |
| Pharmacy Support | Regular adherence counselling | Close relationship with local Apotheken |
| Cross‑Border Purchasing | Occasional for price | Less frequent but present |
Availability And Price Overview
How easy is it to get methotrexate in Austria and what about cost?
Methotrexate tablets, solutions and injectables are widely available in Austrian pharmacies, though the specific brands supplied depend on price regulation and Sozialversicherung reimbursement rules.
Generics play an important role in reducing patient cost, and E‑Medikation ensures prescription tracking and reimbursement claims.
Pharmacies such as BENU and independent Apotheken may stock different brands, and patients sometimes request oral solutions like Jylamvo for paediatric use or prefilled syringes for injection convenience.
Cross‑border purchasing into Germany, Czechia or Hungary continues for price or availability reasons, but reimbursement can be impacted by national rules.
| Product Type | Typical Price Bracket | Reimbursement Notes |
|---|---|---|
| Generic Tablets | Lower cost bracket | Usually covered per Sozialversicherung rules |
| Branded Prefilled Syringes | Higher cost bracket | Reimbursement depends on indication and supplier |
| Oral Solutions (Jylamvo, Xatmep) | Variable | May require documentation for reimbursement |
NOTE: In this online pharmacy, methotrexate is available without a prescription, with discreet delivery to Australia in 5-14 days.
Comparable Medicines And Preferences
Wondering what alternatives exist if methotrexate is not suitable?
Alternatives and adjuncts in inflammatory diseases include leflunomide, sulfasalazine, hydroxychloroquine and biologics such as TNF inhibitors and interleukin inhibitors.
Comparative effectiveness studies in Europe show methotrexate generally remains first‑line for many patients, with biologics reserved for inadequate response or specific prognostic factors.
In Austria, Sozialversicherung criteria and specialist recommendations guide escalation to biologics, and pharmacists counsel on vaccination needs and infection risks before immunomodulator changes.
| Agent | Pros | Cons |
|---|---|---|
| Methotrexate | Proven efficacy, oral and injectable options, cost‑effective | Requires monitoring, contraindicated in pregnancy |
| Leflunomide | Oral, alternative mechanism | Teratogenicity concerns, requires washout in pregnancy planning |
| Biologics | High efficacy in refractory disease | Higher cost, immunisation and infection considerations |
Patients often prefer oral agents for convenience, but subcutaneous methotrexate is chosen when tolerability or absorption is better with that route.
Frequently Asked Questions
Can I become pregnant while taking methotrexate?
No.
Methotrexate is contraindicated during pregnancy and breastfeeding.
Both women and men must discuss conception plans with their specialist and follow washout guidance before attempting pregnancy.
Is alcohol allowed while taking methotrexate?
Alcohol consumption should be minimised or avoided because it increases the risk of liver toxicity.
How often will I need tests while on methotrexate?
Baseline liver function tests, full blood count and renal function are required, with periodic monitoring scheduled by the specialist.
Monitoring frequency depends on dose, comorbidities and concurrent medicines.
What about vaccines?
Live vaccines are generally contraindicated during immunosuppressive therapy with methotrexate.
Inactivated vaccines are recommended and timing should be discussed with the specialist and pharmacist.
When To Call Emergency Services
Call emergency services or seek urgent care for severe breathlessness, chest pain, signs of severe infection such as high fever, severe bleeding, or jaundice.
Patient Counselling Checklist
What should a pharmacist cover when dispensing methotrexate?
- Confirm the prescription states weekly dosing and clarify which weekday the patient will take the dose.
- Explain the importance of folic acid and confirm the prescribed folic acid regimen.
- Review baseline and ongoing monitoring requirements: LFT, CBC, renal function.
- Advise on contraindications, including pregnancy prevention and alcohol avoidance.
- Demonstrate injection technique for prefilled syringes/autoinjectors and provide written instructions.
- Check E‑Medikation for interactions and reconcile OTC medicines and supplements.
- Provide emergency advice for breathlessness, high fever, severe bleeding or jaundice.
| Test | When |
|---|---|
| Baseline LFT, CBC, Renal Function | Before starting methotrexate |
| Ongoing LFT and CBC | At intervals determined by specialist (typically every 2–3 months early phase) |
| Chest Symptoms Review | Immediate review for new cough or breathlessness |
Delivery Across Australia
| City | Region | Delivery time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-9 days |
| Darwin | Northern Territory | 5-9 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-7 days |
| Wollongong | New South Wales | 5-7 days |
| Geelong | Victoria | 5-7 days |
| Sunshine Coast | Queensland | 5-9 days |
| Townsville | Queensland | 5-9 days |
| Cairns | Queensland | 5-9 days |
